在瘤微环境中选择性激活互白素-2/互白素-15受体信号,使用对联双特异性抗体
Julien Montorfani1,2, Eric Hatterer1, Laurence Chatel1
1Light Chain Bioscience - Novimmune S.A, Plan-Les-Ouates, Geneva, Switzerland.
Journal for immunotherapy of cancer
|March 25, 2025
概括
这项研究开发了双特异性抗体 (bsAbs),以向癌症免疫疗法中的介质素-2 (IL-2) 和介质素-15 (IL-15). 新的bsAbs选择性地激活瘤内的免疫细胞,减少全身毒性并增强抗瘤作用.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 互白蛋白-2 (IL-2) 和-15 (IL-15) 在癌症免疫疗法中对免疫细胞激活至关重要.
- 由于严重的毒性和管理挑战,IL-2和IL-15的治疗用途受到限制.
- 针对IL-2R/IL-15R和瘤相关抗原 (TAA) 的双特异性抗体 (bsAbs) 已开发,以提高安全性和疗效.
研究的目的:
- 在瘤微环境中创建和评估新的bsAb对,以有针对性地激活IL-2/IL-15通路.
- 与传统的IL-2疗法相比,评估这些bsAbs的体外和体内疗效和安全性.
- 为了研究bsAbs与检查点抑制剂结合用于增强抗瘤活性的潜力.
主要方法:
- 构建了针对CD122/CD132和特定TAA (HER2,MSLN) 的bsab对.
- 进行了体外测试,以证实对抗性活性和T细胞介导的杀死.
- 在合成基因小鼠模型中评估了体内生物活性,全身毒性和抗瘤疗效,包括与抗mPD-1疗法结合治疗.
主要成果:
- bsAb对仅在TAA+瘤细胞的存在下表现出选择性免疫细胞激活.
- CD122×MSLN-1/CD132×MSLN-2 bsAb对激活了瘤内的NK细胞和CD8+T细胞,没有系统性毒性.
- 与抗mPD-1的联合治疗显著增加了效应细胞的积累,并抑制了瘤的生长.
结论:
- 开发的bsAbs有效地利用IL-2/IL-15通路进行抗瘤活性,同时减轻全身毒性.
- 这种双特异性抗体格式显示出在癌症免疫治疗中更广泛的应用的前景.
- 通过bsAbs进行向免疫激活是一种创新的策略,可以克服基于细胞因子的治疗方法的局限性.
更多相关视频
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
14.7K
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
548
相关概念视频
Tumor Immunotherapy
450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
